Posted by Michael Wonder on 12 Jun 2020
ICER to assess treatments for high cholesterol
12 June 2020 - Report will be subject of a Midwest CEPAC meeting in February 2021; ppen Input now being accepted until June 30, 2020 —
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol, Esperion Therapeutics) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD.
Inclisiran is currently undergoing FDA review, with an anticipated decision expected at the end of this year. Bempedoic acid received FDA approval in February 2020.
